Table 2.
Human Immunodeficiency Virus Type 1 (HIV-1) Gag–Specific Interferon γ (IFN-γ) Enzyme-Linked Immunospot–Determined T-Cell Responses 2 Weeks After the First and Second Vaccinations
| Group | 2 Weeks After First Vaccination |
2 Weeks After Second Vaccination |
||||||
|---|---|---|---|---|---|---|---|---|
| Subjects, No. | Response Rate,a Subjects, No. (%) | Geometric Mean Responseb (95% CI) | Range of Positive Responsesb | Subjects, No. | Response Rate,a Subjects, No. (%) | Geometric Mean Responseb (95% CI) | Range of Positive Responsesb | |
| SLA | 10 | 0 (0) | 3 (2–5) | … | 12 | 12 (100) | 275 (138–546) | 53–1740 |
| SHA | 11 | 0 (0) | 2 (1–5) | … | 11 | 10 (91) | 222 (101–488) | 60–1061 |
| SA | 21 | 0 (0) | 3 (2–4) | … | 23 | 22 (96) | 248 (154–400) | 53–1740 |
| ASH | 11 | 6 (55) | 54 (25–120) | 48–381 | 11 | 6 (55) | 59 (30–113) | 43–485 |
| SHSH | 12 | 0 (0) | 3 (2–7) | … | 12 | 0 (0) | 4 (2–8) | … |
| Placebo | 17 | 0 (0) | 2 (1–3) | … | 16 | 0 (0) | 2 (1–4) | … |
Abbreviations: Ad35-GRIN, adenovirus 35–vectored vaccine encoding HIV-1 Gag, reverse transcriptase, integrase, and Nef; ASH, Ad35-GRIN prime followed by SeV-Gag boost; CI, confidence interval; HIV-1, human immunodeficiency virus type 1; SA, SHA and SLA groups combined; SHA, higher-dose SeV-Gag prime and Ad35-GRIN boost; SHSH, higher-dose SeV-Gag prime and boost; SLA, lower-dose SeV-Gag prime and Ad35-GRIN boost; SeV-Gag, Sendai virus–vectored vaccine encoding HIV-1 Gag.
a Excludes samples in which the prevaccination values for the Gag peptide pool were positive (ie, cross-reactive).
b Data are IFN-γ spot-forming units per million peripheral blood mononuclear cells.